LifeMD Q2 2026 revenue within guidance of $47M-$50M
The company reported $47.3 million in revenue and a gross margin expansion to 89% as it transitions to branded GLP-1 therapies, while reiterating expectations for a return to positive adjusted EBITDA in the second half of 2026.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day